Evergreen Theragnostics Secures $26M to Drive Radiopharmaceutical Innovation
April 18, 2024, 9:31 am
Evergreen Theragnostics, a cutting-edge radiopharmaceutical company based in Springfield, NJ, has successfully completed a $26M capital raise, with support from Petrichor and LIFTT. This funding will propel the company's groundbreaking research pipeline into clinical trials, facilitate the commercial launch of its diagnostic agent, and enhance its Contract Development and Manufacturing (CDMO) services.
Led by CEO James Cook, Evergreen Theragnostics is dedicated to revolutionizing cancer treatment through the development of innovative radiopharmaceuticals. The company's strategic focus on advancing theragnostic solutions for cancer patients underscores its commitment to improving outcomes and quality of life.
With plans to launch the diagnostic agent Octevy™ pending FDA approval, Evergreen is poised to make a significant impact in the field of radiopharmaceuticals. Additionally, the company is gearing up to initiate therapeutic and diagnostic clinical trials for its novel radiopharmaceutical pair, Lutetium-177 (177Lu) EVG-321 and Gallium-68 (68Ga) EVG-321, offering hope to individuals battling small cell lung cancer.
James Cook expressed his enthusiasm for the future, stating, "This new funding will enable us to rapidly progress our novel theragnostic pair, EVG-321, into clinical trials. Our CDMO business is gaining momentum, and we are grateful for the support of our shareholders in advancing our mission."
Evergreen's commitment to scientific excellence, coupled with its experienced team of industry leaders, positions the company as a frontrunner in the radiopharmaceutical landscape. By leveraging this capital infusion to drive innovation and expand its capabilities, Evergreen Theragnostics is poised to make a lasting impact on cancer care.
As the company continues to push the boundaries of radiopharmaceutical research and development, its dedication to improving patient outcomes remains unwavering. Evergreen Theragnostics is a beacon of hope for individuals facing cancer, offering cutting-edge solutions that have the potential to transform the treatment landscape.
Led by CEO James Cook, Evergreen Theragnostics is dedicated to revolutionizing cancer treatment through the development of innovative radiopharmaceuticals. The company's strategic focus on advancing theragnostic solutions for cancer patients underscores its commitment to improving outcomes and quality of life.
With plans to launch the diagnostic agent Octevy™ pending FDA approval, Evergreen is poised to make a significant impact in the field of radiopharmaceuticals. Additionally, the company is gearing up to initiate therapeutic and diagnostic clinical trials for its novel radiopharmaceutical pair, Lutetium-177 (177Lu) EVG-321 and Gallium-68 (68Ga) EVG-321, offering hope to individuals battling small cell lung cancer.
James Cook expressed his enthusiasm for the future, stating, "This new funding will enable us to rapidly progress our novel theragnostic pair, EVG-321, into clinical trials. Our CDMO business is gaining momentum, and we are grateful for the support of our shareholders in advancing our mission."
Evergreen's commitment to scientific excellence, coupled with its experienced team of industry leaders, positions the company as a frontrunner in the radiopharmaceutical landscape. By leveraging this capital infusion to drive innovation and expand its capabilities, Evergreen Theragnostics is poised to make a lasting impact on cancer care.
As the company continues to push the boundaries of radiopharmaceutical research and development, its dedication to improving patient outcomes remains unwavering. Evergreen Theragnostics is a beacon of hope for individuals facing cancer, offering cutting-edge solutions that have the potential to transform the treatment landscape.